

Daftar Pustaka

1. Goldstein B, Grior B, Randolp A. International pediatric sepsis consensus conferences : definition for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med*. 2005;4:2-8.
2. Rismala D. Sepsis pada anak : pola kuman dan uji kepekaan. *Maj KedoktIndon*. 2011;61:101-6.
3. Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ, Abraham E, Trzeciak S, et al. Severe sepsis and septic shock: review of the literature and emergency. *Ann Emerg Med* 2006; 48(1):28-54.
4. Thomas NJ, Tamburo RF, Hall MW, Rajasekaran S, Venglarcik JS. Bacterial sepsis and mechanism of microbial pathogenesis. Dalam: Nicholas DG, penyunting, Roger's *Textbook of Pediatric Intensive Care*. Edisi ke-4. Baltimore: Lippincott Williams & Wilkins. 2008;477-88
5. Watson RS, Carcillo JA, Linde-Zwirble WT, Clerment G, Lidicker J. The epidemiology of severe sepsis in children in the united states. *Am J Respir Crit Care Med*. 2003;167:695-701.
6. Yuniar I, Dewi R, Pudjiadi A. Epidemiology of pediatric sepsis in pediatric intensive care unit FKUI-RSCM. *Pediatr Indones*. 2010;50(2):1-8.
7. Nurnaningsih, Setyowireni D, Rusmawatingtyas D. Microbial pattern in pediatrics septicaemia at pediatric intensive care unit Sardjito Hospital. *Paediatr Indones*. 2011;51:92.
8. Somasetia DH. Tatalaksana awal sepsis berat dan syok sepsis anak. Dalam : Tatalaksana awal kegawatan pada bayi dan anak. PKB IDAI cabang Sumatera Utara/ Departemen IKA fakultas kedokteran USU. 2012;38-61.
9. Joseph A, Carcillo MD. Pediatric septic shock and multiple organ failure. *Crit Care Clin*. 2003;19:413-40.
10. Venet F, Lepape A, Monneret G. Clinical review : flow cytometry perspective in the ICU – from diagnosis of infection to monitoring of injury-induced immune dysfunctions. *Critic Care*. 2011;231:1-9.
11. Gibot S, Bene MC, Noel R. Combination biomarkers to diagnose sepsis in the critically ill patient. *Am J Respir Crit Care Med*. 2012;186:65-71.
12. Pierrekos C, Vincent JL. Sepsis biomarkers : a review. *Crit Care*. 2010;14:1-18.
13. Icardi M, Erickson Y, Kilborn S, Stewart B, Grief B, Schamweber G. CD64 provides simple and predictive testing for detection and monitoring of sepsis and bacterial infection in hospital patients. *J Clin Microbiol*. 2009;47:3914-9
14. Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. *Expert rev Anti Infect Ther*. 2011;9:71-9
15. Allen E, Bakke AC, Purtzer MZ, Deodhar A. Neutrophil CD64 expression : distinguishing acute inflammatory autoimmune disease from systemic infections. *Ann Rheum Dis*. 2002;61:522-25.
16. Chan T, Gu F. Early diagnosis of sepsis using serum biomarkers. *Expert Rev Mol Diagn*. 2011;11:487-96.
17. Khilnani P, Deopujari S, Carcillo J. Recent advances in sepsis and septic shock. *Indian J of Pediatrics*. 2008;75:821-30.
18. Agilli M, Sener I, Yesidal F, Honca T, Aydin I, Akgul EO, et al. A new marker for diagnosis of sepsis: presepsin. *J Investig Biochem*. 2012;1(1):55-57

19. Endo S, Suzuki Y, Takahashi G, Shozushima T, Murai A. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. *J Infect Chemoter.* 2011;17:764-9
20. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S: Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. *J Infect Chemoter.* 2011;17(6):764-769.
21. Khilnani P, Deopujari S, Carcillo J. Recent advances in sepsis and septic shock. *Indian J of Pediatr.* 2008;75:821-30.
22. Li S, Huang X, Chen Z. Neutrophil CD64 expression as a biomarker in the early diagnosis of bacterial infection: a meta-analysis. *Int J of Infect Dis.* 2013;17:e12-23.
23. Carvalho PR, Feldens L, Seitz EE, Rocha TS, Soledade MA, Trotta EA. Prevalence of systemic inflammatory syndromes at a tertiary pediatric intensive care unit. *Journal de Pediatria* 2005;81(2).
24. Proulx F, Fayon M, Farrel CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. *Chest* 1996;109:1033-7.
25. Carcillo JA. Searching for the etiology of Systemic inflammatory response syndrome: is SIRS occult endotoxemia. *Intensive Care Med.* 2006;32:181-4.
26. Pavare J, Grope I, Gardovska D. Prevalence of systemic inflammatory response syndrome (SIRS) in hospitalized children: A point prevalence study. *BMC Pediatrics.* 2009;25(9).
27. Castellheim A, Brekke O-L, Espevik T, Harboe M, Mollnes T. Innate immune responses to danger signals in Systemic Inflammatory Response Syndrome and sepsis. *Journal of Immunology* 2009;69:479-91.
28. Enrione MA, Powell KR. Sepsis, septic shock, and systemic inflammatory response syndrome. Dalam : Kliegman RM, Behrman RE, Jenson HB, Stanton BF, penyunting. *Nelson textbook of pediatrics.* Edisi ke-18. Philadelphia: WB Saunders, 2007;1094-9.
29. Wynn JL, Wong HR. Pathophysiology and treatment of septic shock in neonates. *Clin Perinatol.* 2010;37:439-79.
30. Carcillo JA. Pediatric septic shock and multiple organ failure. *Crit Care Clin.* 2003;19:413-40
31. Russell J. Management of sepsis. *NEJM* 2006;355(16):1699-713.
32. Winn J, Cornell T, Wong H, Shanley T, Wheeler D. The host response to sepsis and developmental impact. *Pediatrics* 2010;125(5):1031-8.
33. Glauser MP. Pathophysiology basis of sepsis: considerations for future strategies of intervention. *J Crit Care Med.* 2000;28:4-8
34. Wong HR, Cvijanovich N, Wheeler DS. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. *Am J Respir Crit Care Med.* 2008;1-3.
35. Millar BC, Jiru X, More JE, Earle JAP. A simple and sensitive method to extract bacterial, yeast and fungal DNA from blood culture material. *J Microbiol Methods.* 2000;42:139-47.
36. Estenssoro E, Gonzalez F, Laffaire E, et al. Shock on admission day is the best predictor of prolonged mechanical ventilation in the ICU. *Chest.* 2005;127:598-603.
37. BATTERY JP. Blood cultures in newborns and children: Optimizing an every day test. *Arct Dist Child Fetal Neonatal.* 2002;87:25-8.
38. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S. Evaluation of a newly identified soluble CD 14 subtype as a marker for sepsis. *J Infect Chemoter* 2005; 11:234-8.

39. Zou Q, Wen W, Zhang CX. Presepsin as a novel sepsis biomarker. *World J Emerg Med* 2014; 5(1): 16-19
40. Shirakawa K, Naitou K, Hirose J, Takahashi T, Furusako S. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. *Clin Chem Lab Med* 2011; 49:937-939.
41. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. *J Matern Fetal Neonatal Med* 2011; 24:12-14.
42. Ramana KV, Pinelli VB, Kandi S, Asha G, Jayashankar CA et al. Presepsin: a novel and potential diagnostic marker for sepsis. *Am J Med Biologic Research*. 2014; 2(4): 97-100
43. Ulla M, Pizzalato E, Luchiaro M, Loiacono M, Soardo M. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department. *Crit Care*. 2013; 17:1-8.
44. Bazil V, Strominger JL. Shedding as a mechanism of down modulation of CD14 on stimulated human monocytes. *Eur J Immunol*. 1991; 147: 1567-74
45. Endo S, Takahashi G, Shozushima T, Matsumoto N, Kojika M, et al. Usefulness of presepsin (soluble CD 14 subtype) as a diagnostic marker for diagnostic sepsis. *JJAAM* 2012; 23:27-38.
46. Bufler P, Stiegler G, Schuchamann M, et al: Soluble lipopolysaccharide receptor (CD 14) is released via two mechanisms from human monocytes and CD 14 transfectants. *Eur J Immunol*. 1995; 25: 604-10.
47. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. *J Antimicrob Chemother*. 2011; 66: ii33-ii40.
48. Spanuth E, Ebelt H, Ivandic B, Werdan K. Diagnostic and prognostic value of presepsin (soluble cd14 subtype) in emergency patients with early sepsis using the new assay P-ATHFAST Presepsin. *IFCC-World Lab-Euro Med Lab, Berlin*, 2011: 15-19.
49. Pizzalato E, Ulla M, Galuzzo C, Luchiaro M, Manetta T, Lupia E, et al. Role of presepsin for the evaluation of sepsis in the emergency department. *Clin Chem Lab Med*. 2014; 52(10): 1395-1400.
50. Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department. *Crit Care* 2013; 17:R244.
51. Novelli G, Morabito V, Ferretti G, Pugliese F, Ruberto F, Venuta F, et al. Pathfast presepsin assay for early diagnosis of bacterial infections in surgical patients: preliminary study. *Transplant Proc* 2013; 45:2750-3.
52. Ishikura H, Nishida T, Murai A, Nakamura Y, Irie Y, Tanaka J, et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. *Crit Care* 2014; 18:R19.
53. Popov DA, Pliushch MG, Ovseenko ST, Abramian MV, Podshchekoldina OO, Iarustovskii MB. SCD14-ST (presepsin) level monitoring in cardiac surgical patients during perioperative period. *Anesteziol Reanimatol*. 2013; 3:30-5.
54. Vodnik T, Kaljevic G, Tadic T, Majkic-Singh N. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. *Clin Chem Lab Med*. 2013; 51:2053-62.
55. Mussap M, Puxeddu E, Burrai P, Noto A, Cibecchini F, Testa M, et al. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. *J Matern Fetal Neonatal Med* 2012; 25:51-3.
56. Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. *Jof Biomed Informatics*. 2014; 48:193-204.

57. Buderer NM. Statistical methodology : incorporating the prevalence of disease into sample size calculation for sensitivity and specificity. *Acad Emerg Med.* 1996;3:895-900.
58. Obuchowski NA. Sample size calculation in studies of test accuracy. *Stat Methods Med Res.* 1998;7:371-92.
59. Souza D, Shieh HH, Troster EJ. Comparisons in the epidemiology and outcomes of pediatric septic patients admitted to public and private hospitals in Latin America. *Pediatr Crit Care Med.* 2014;15:18-19.
60. Gholamali G. Procalcitonin role in differential diagnosis in infection stages and non infection inflammation. *PakJBiolSci.* 2009; 12 (4): 393–6.
61. Sinha M, Desai S, Mantri S, Kulkarni A. Procalcitonin as an adjunctive biomarker in sepsis. *Indian journal of anaesthesia.* 2011;55:266-70
62. Alizadeh AM, Movahed RK, Mohammadnia M. Comparative evaluation of conventional and bactec methods for detection of bacterial infection. *Tanaffos.* 2016;15(2):112-16.
63. Mir BA, Sirwar SB, Indupalli AS. A comparative study of conventional method versus bactec method in bacteriological profile of septicemia. *Int J Bioassays.* 2013;02(12);1541-5.
64. Hendriantingtyas, Banundari RH, Indranila KS, Budiwijoyo I. Procalcitonin, CRP dan presepsin serum di SIRS. *Indonesian journal of clinical pathology.* 2014;20(3):181-89.
65. Osman AS, Awadallah MG, Tabl HA, Abed NT, Goudah ES. Presepsin as novel diagnostic marker in neonatal septicemia. *Egyptian journal of medical microbiology.* 2015;24(3):2015.21-26.
66. Stubljar D, Rogina P, Skvarc M, Pavlovic A. Diagnostic accuracy of sCD14 (presepsin) is comparable to procalcitonin (PCT) for the diagnosis of bacterial infections in critically ill patients. 2013.
67. Baraka A, Zakaria M. Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies, *Int. J.Hematol.* (2018) 1–8.
68. Kaiserova E, Kolenova A. The role of CRP, PCT, IL-6 and presepsin in early diagnosis of bacterial infectious complications in paediatric haemato-oncological patients, *Neoplasma* 63 (2016).
69. Caironi P, Masson M. Compared values of presepsin (sCD14-ST) and procalcitonin as early markers of outcome in severe sepsis and septic shock: a preliminary report from the Albumin Italian Outcome Sepsis (ALBIOS) study. *Crit Care* 2013; 17 (Suppl 2): P35.
70. Carpio R, Zapata J, Spanuth E, Hess G. Utility of presepsin as a diagnostic and prognostic marker of sepsis in the emergency department. *Clin Chim Acta.* 2015;450:169-75.
71. Kim H, Hur M, Moon HW, Yun YM, Di Somma S. Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. *Ann Intensive Care.* 2017; 7(1):27